Live Breaking News & Updates on Biomarin Novato

BioMarin Announces First Quarter 2021 Financial Results and Corporate Updates
- Full-year 2021 Financial Guidance Reaffirmed
- Total Revenues Grew 9% in the First Quarter 2021 Compared to First Quarter 2020, Excluding Kuvan
- Regulatory Actions in Europe for Vosoritide and Valoctocogene Roxaparvovec Tracking as Expected; BioMarin Anticipates CHMP Opinion in June for Vosoritide and June Re-submission of MAA for Valoctocogene Roxaparvovec
- FDA Review of Vosoritide Proceeding; PDUFA Target Action Date Extended to November 20, 2021 to Provide Time for Review of Recently Submitted 2-year Phase 3 Results
News provided by
Share this article
Financial Highlights (in millions of U.S. dollars, except per share data, unaudited) ....

United States , Sanofi Genzyme , Debra Charlesworth , Biomarin Novato , Traci Mccarty , Jean Jacques Bienaim , Allen Institute , Biomarin Pharmaceutical Inc , Replay International Number , Company Annual Report On Form , Biomarin Genzyme , Allen Institute Collaboration , Committee For Medicinal Products Human Use , Drug Administration , European Commission , Development Expense , Exchange Commission , International Number , European Medicines Agency , Development Portfolio , Months Ended March , Product Revenues Marketed , Generally Accepted Accounting Principles , Net Product Revenues , Marin Pharmaceutical , Chief Executive Officer ,